RT Journal Article
SR Electronic
T1 The spatial and temporal distribution of SARS-CoV-2 from the built environment of COVID-19 patient rooms: A multicentre prospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.23.22282241
DO 10.1101/2022.11.23.22282241
A1 Fralick, Michael
A1 Burella, Madison
A1 Hinz, Aaron
A1 Mejbel, Hebah S.
A1 Guttman, David S.
A1 Xing, Lydia
A1 Moggridge, Jason
A1 Lapp, John
A1 Wong, Alex
A1 Nott, Caroline
A1 Harris-Linton, Nicole
A1 Kassen, Rees
A1 MacFadden, Derek
YR 2022
UL http://medrxiv.org/content/early/2022/11/27/2022.11.23.22282241.abstract
AB Background SARS-CoV-2 can be detected from the built environment (e.g., floors), but it is unknown how the viral burden changes over space and time surrounding an infected patient. Characterising these data can help advance our understanding and interpretation of surface swabs from the built environment.Methods We conducted a prospective study at two hospitals in Ontario, Canada between January 19, 2022 and February 11, 2022. We performed serial floor sampling for SARS-CoV-2 in rooms of patients newly hospitalized with COVID-19 in the past 48 hours. We sampled the floor twice daily until the occupant moved to another room, was discharged, or 96 hours had elapsed. Floor sampling locations included: 1m from the hospital bed, 2m from the hospital bed, and at the room’s threshold to the hallway (typically 3 - 5m from the hospital bed). The samples were analyzed for the presence of SARS-CoV-2 using qPCR. We calculated the sensitivity of detecting SARS-CoV-2 in a patient with COVID-19, and we evaluated how the percentage of positive swabs and the cycle threshold of the swabs changed over time. We also compared the cycle threshold between the two hospitals.Results Over the 6-week study period we collected 164 floor swabs from the rooms of 13 patients. The overall percentage of swabs positive for SARS-CoV-2 was 93% and the median cycle threshold (for positive swabs) was 33.7 (IQR: 30.9, 37.5). On day 0 of swabbing the percentage of swabs positive for SARS-CoV-2 was 81.1% and the median cycle threshold was 33.7 (IQR: 32.1, 38.3) compared to swabs performed on day 2 or later where the percentage of swabs positive for SARS-CoV-2 was 98.1% and the cycle threshold was 33.4 (IQR: 30.7, 35.7). We found that viral detection did not change with increasing time (since the first sample collection) over the sampling period, OR 1.65 per day (95% CI 0.68, 4.02; p = 0.27). Similarly, viral detection did not change with increasing distance from the patient’s bed (1m, 2m, or 3m), OR 0.85 per metre (95% CI 0.38, 1.88; p = 0.69). The cycle threshold was lower (e.g. more virus) in The Ottawa Hospital (median Cq 30.8) where the floors are cleaned once daily rather than the Toronto hospital (median Cq 37.3) where floors were cleaned twice daily.Conclusions We were able to detect SARS-CoV-2 on the floors of rooms of patients with COVID-19 and the viral burden did not vary over time or by distance from the bed. These results suggest floor swabbing for the detection of SARS-CoV-2 in a built environment such as a hospital room is both accurate and robust to variation in sampling location and duration of occupancy.Competing Interest StatementMike Fralick is a consultant for ProofDx, a start-up company that has created a point-of-care device for COVID-19 using CRISPR.Funding StatementThis study was funded by CIHR, Sinai Health Department of Medicine Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors